The majority of cancers studied have shown increased expression of VEGF, including haematological malignancies [14]; colon and rectal cancers [15]; liver cancers [16]; lung, breast, thyroid, gastrointestinal tract, kidney and bladder cancers; angiosarcomas; ovary and uterine cervix carcinomas; germ cell tumours; and intracranial tumours [17]. This evidence concerns the gene VEGFA and urinary bladder carcinoma.